Drugs / GD2/GD3 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00911560 | May 2009 → May 2027 expected | neuroblastoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GD2/GD3 vaccine | “They received seven subcutaneous injections of GD2/GD3 vaccine spanning 1 year plus oral β-glucan starting at week 6 after the third dose of vaccine.” PMID 33326254 ↗ Dec 2020 |
| Known as | bivalent vaccine | “The main treatment in this protocol is a vaccine. It is called a " bivalent vaccine" which means it has 2 antigens.” NCT00911560 ↗ |
| Action | Deplete | “Then, the attached antibodies would attract the patient's white blood cells to kill the neuroblastoma.” NCT00911560 ↗ |
| Modality | Vaccine | “The main treatment in this protocol is a vaccine.” NCT00911560 ↗ |
| Route | Subcutaneous | “Patients with neuroblastoma in ≥2nd complete/very good partial remission received vaccine subcutaneously” PMID 24520094 ↗ Feb 2014 |